MDWD - メディウ―ンド （MediWound Ltd.） メディウ―ンドMDWDのチャート
MDWDの企業情報
| symbol | MDWD |
|---|---|
| 会社名 | Mediwound Ltd. （メディウ―ンド） |
| 分野（sector） | Consumer Durables 耐久消費財 |
| 産業（industry） | Specialty Chemicals |
| 業種 | 医薬品 医療関連（Health Care） |
| 概要 | 事業概要 MediWound Ltd. is a biopharmaceutical company. The Company focuses on developing manufacturing and commercializing therapeutics products in the fields of severe burns chronic and other hard-to-heal wounds connective tissue disorders and other indications. The Company''s product NexoBrid is indicated for the removal of dead or damaged tissue known as eschar in adults with deep partial- and full-thickness thermal burns also referred to as severe burns. The Company sells NexoBrid in Europe and Israel. NexoBrid is a topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues. Its product EscharEx is a topical biological drug which is being developed for debridement of chronic and other hard-to-heal wounds. NexoBrid and EscharEx are based on its proteolytic enzyme technology. The Company is also developing an injectable product based on its proteolytic enzyme technology for connective tissue pathologies and indications. メディウ―ンドはイスラエルのバイオ医薬品会社。重度熱傷、慢性疾患、その他治癒が困難な創傷、膠原病などの分野で有効な治療法がない医療ニ―ズに対応する製品の開発、製造、商業化に従事する。同社のバイオ医薬品｢NexoBrid｣は痂皮の切除用製品として、欧州医薬品庁から承認済みである。 MediWound is a biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration. Its strategy is centered around its validated enzymatic platform technology, focused on next-generation bio-active therapies for burn and wound care and biological medicinal products for tissue repair. |
| 本社所在地 | 42 Hayarkon Street Yavne 8122745 ISR |
| 代表者氏名 | Stephen T. Wills スティーブン・T・ウィルズ |
| 代表者役職名 | Chairman of the Board 取締役会会長 |
| 電話番号 | +972 8-932-4010 |
| 設立年月日 | 36526 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2014年 |
| 従業員数 | 76人 |
| url | www.MediWound.com |
| nasdaq_url | https://www.nasdaq.com/symbol/mdwd |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -12.75100 |
| 終値（lastsale） | 6.36 |
| 時価総額（marketcap） | 172857416.04 |
| 時価総額 | 時価総額（百万ドル） 165.24730 |
| 売上高 | 売上高（百万ドル） 2.82000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 138.24330 |
| 当期純利益 | 当期純利益（百万ドル） -14.47300 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Mediwound Ltd revenues increased 26% to $1.6M. Net loss decreased 1% to $8.7M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Research and development net decrease of 65% to $1.2M (expense) General and administrative decrease of 40% to $989K (expense). |
MDWDのテクニカル分析
MDWDのニュース
MediWound completes enrollment for interim assessment of mid-stage EscharEx study 2021/06/09 20:37:43 Seeking Alpha
MediWound Completes Patient Enrollment for Interim Assessment of its U.S. EscharEx Phase 2 Adaptive Design Study 2021/06/09 20:30:00 Intrado Digital Media
Interim Assessment Expected by end of July 2021 and Completion of Enrollment by Year-End 2021 Interim Assessment Expected by end of July 2021 and Completion of Enrollment by Year-End 2021
MediWound Completes Patient Enrollment for Interim Assessment of its U.S. EscharEx Phase 2 Adaptive Design StudyInterim Assessment Expected by end of July 2021 and Completion of Enrollment by Year-End 2021 2021/06/09 00:00:00 BioSpace
MediWound Ltd. (Nasdaq: MDWD), today announced that the enrollment target of patients for an interim assessment of its EscharEx® U.S. phase 2 adaptive design study for the treatment of venous leg ulcers (VLUs) has been achieved, and interim assessment is expected by the end of July 2021.
MediWound Announces Peer-Reviewed Paper of a Case Series Report of Basal Cell Carcinoma Published in the Open Dermatology Journal 2021/06/07 00:00:00 BioSpace
MediWound Ltd., a fully-integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair and regeneration, announced that a peer-reviewed publication of a case series report of basal cell carcinoma destruction by a concentrate of proteolytic enzymes enriched in bromelain has been published in the Open Dermatology Journal.
MediWound signs UAE burns treatment distribution deal 2020/12/15 12:36:53 Globes English
Under the terms of the agreement, Ghassan Aboud Group will have exclusive rights to market and distribute NexoBrid in the UAE.
MediWound to Report Third Quarter 2020 Financial Results and Host a Conference Call and Webcast on November 10, 2020 2020/11/02 21:01:00 GlobeNewswire
YAVNE, Israel, Nov. 02, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative…
Wound Debridement Market Size Estimation, Outbreak Impact Analysis, Key Insights and Application By 2027 | Coloplast, Misonix, Smith & Nephew, Medtronic, MediWound 2020/10/06 15:31:06 OpenPR
Increase in aging population, rise in prevalence of diabetes escalates incidence of chronic wounds, and growth in obesity levels drive the market. In addition, reimbursement policy and rise in demand for better healthcare fuels the market. However, possible complications after
MediWound to Report Second Quarter 2020 Financial Results and Host a Conference Call and Webcast on August 6, 2020 2020/07/28 12:00:00 GlobeNewswire
YAVNE, Israel, July 28, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative…
MediWound : Company Factsheet | MarketScreener 2020/06/07 15:51:03 MarketScreener
MediWound Snapshot Validated breakthrough platform technology with commercial product - NexoBrid®, and promising late-stage product… | June 7, 2020
MediWound to Report Third Quarter 2020 Financial Results and Host a Conference Call and Webcast on November 10, 2020 2020/11/02 21:01:00 GlobeNewswire
YAVNE, Israel, Nov. 02, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative…
Wound Debridement Market Size Estimation, Outbreak Impact Analysis, Key Insights and Application By 2027 | Coloplast, Misonix, Smith & Nephew, Medtronic, MediWound 2020/10/06 15:31:06 OpenPR
Increase in aging population, rise in prevalence of diabetes escalates incidence of chronic wounds, and growth in obesity levels drive the market. In addition, reimbursement policy and rise in demand for better healthcare fuels the market. However, possible complications after
MediWound to Report Second Quarter 2020 Financial Results and Host a Conference Call and Webcast on August 6, 2020 2020/07/28 12:00:00 GlobeNewswire
YAVNE, Israel, July 28, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative…